Prescription Dermatology
Deucravacitinib (SOTYKTU)
Oral selective allosteric TYK2 inhibitor
Duration
経口1 days1 sessions
Downtime
なし
Sessions
継続oral (効果判定は通常16 weeks以降)
About This Treatment
Deucravacitinib is an oral selective TYK2 inhibitor for moderate-to-severe plaque psoriasis. It is designed to provide pathway selectivity compared with broader JAK inhibition.
Mechanism of Action
Allosteric binding to TYK2 regulatory domain dampens IL-23/IL-12/type I IFN signaling implicated in psoriatic inflammation.
Indications
General indication (see detailed description)
Expected Results
POETYK trials reported durable efficacy through 52 weeks, 2 years, and 3 years with maintained PASI and sPGA responses.
Clinical Evidence
Armstrong AW, et al. (2024)
POETYK PSO-1/PSO-2 long-term deucravacitinib outcomes. J Am Acad Dermatol
Clinical improvement was reported in this study (see original paper for details).
Lebwohl M, et al. (2024)
Pooled 52-week safety of deucravacitinib in phase 3 trials. J Dermatolog Treat
Clinical improvement was reported in this study (see original paper for details).
U.S. FDA (2022)
SOTYKTU prescribing information. FDA label
Clinical improvement was reported in this study (see original paper for details).
Risks & Side Effects
Upper respiratory infections, headache, and liver enzyme elevations may occur. TB/infection screening and routine monitoring are recommended.
Interested in this treatment?
Start with an AI skin analysis to check your current skin condition